Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes (PREDICTIVE™)

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir

Study type: Observational

Funder types: Industry

Identifiers

NCT01545791

NN304-1952

Details and patient eligibility

About

This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.

Enrollment: 1,037 patients

Sex: All

Ages: Under 110 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with type 1 or type 2 diabetes mellitus, including newly diagnosed patients who had never received insulin or an insulin analogue before

Exclusion criteria

• Patients whom the physician considered might be noncompliant for any reason; for example, uncooperative attitude, inability to return for the final visit and similar
• Patients previously enrolled in this study
• Patients with a hypersensitivity to insulin detemir

Trial design

1,037 participants in 1 patient group

Insulin detemir users

Treatment:

Drug: insulin detemir